A 40-year-old newly diagnosed type 2 diabetic also has non-alcoholic fatty liver disease (NAFLD). Among the antidiabetic agents below, which has the strongest evidence for histological improvement (reduction in NAFLD activity score and fibrosis) and what is its proposed hepatic mechanism?

• A Pioglitazone — activates PPARgamma in hepatocytes and adipocytes, redistributing fat away from visceral/hepatic depots and reducing hepatic inflammation and fibrosis ✓
• B Metformin — activates hepatic AMPK, reducing lipid synthesis and improving fatty change
• C SGLT2 inhibitors — reduce hepatic glucose output and thereby substrate for de novo lipogenesis
• D DPP-4 inhibitors — increase hepatic GLP-1 signaling, activating AMPK and reducing hepatic steatosis

Explanation

Among currently approved antidiabetics, pioglitazone has the strongest evidence for histological improvement in NASH (non-alcoholic steatohepatitis). The PIVENS trial demonstrated that pioglitazone significantly improved all histological features of NASH including fibrosis stage. Pioglitazone activates PPARgamma (peroxisome proliferator-activated receptor gamma), which: (1) redirects free fatty acids into peripheral adipose tissue, reducing hepatic lipid influx; (2) reduces adipocyte TNF-alpha and IL-6 production (reducing hepatic inflammation); (3) directly activates PPARgamma in hepatic stellate cells reducing fibrogenesis; (4) improves hepatic insulin sensitivity. AASLD guidelines endorse pioglitazone as an option for biopsy-proven NASH. While metformin, SGLT2i, and GLP-1RAs have promising data, pioglitazone remains the best-evidenced approved agent.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.